According to the research by Rodriguez-Irizarry et al. [45], the HIV/SU5416 model established in HIV-infected humanized mice treated with the synthetic inhibitor of vascular endothelial growth factor receptor-2 (SU5416) may be one of the best models for studying pulmonary hypertension and pulmonary vascular diseases. Here, KDR is linked to pulmonary arterial hypertension.